Back to Catalog
Ambrosia Biosciences
ambrosiabio
Oral small molecule GLP-1 drug discovery for obesity and metabolic disease.
Total Funding
$125M
sector:biotech
stage:series_b
GLP-1
oral-small-molecule
obesity
cardiometabolic
GPCR
cryo-EM
ai-drug-discovery
preclinical
Array-BioPharma
Merck-strategic
Boulder-CO
Full Profile Gated
Register as a Qualified Purchaser to access the full profile of Ambrosia Biosciences, including financial analysis, competitive landscape, and investment thesis.